Pirtobrutinib vs Zanubrutinib: When to Reassess Disease Biology and Consider Alternative Classes
Treatment for B-cell malignancies, particularly Chronic Lymphocytic Leukemia (CLL) and certain lymphomas, has evolved rapidly over the past decade. Bruton’s tyrosine kinase (BTK) inhibitors now sit at the center of many treatment strategies. As more agents become available, comparisons such as Pirtobrutinib vs Zanubrutinib are becoming increasingly relevant in real-world clinical decision-making. While both drugs […]








